Remission in RA cuts costs

Rheumatoid arthritis is a chronic, inflammatory, autimmune, systemic disease that affects approximately 2 million Americans.

According to a study of 1,315 patients with rheumatoid arthritis participating inrheumatoid-arthritis-hand the Alberta Biologics Pharmacosurveillance program, patients with who go into remission have increased levels of activity and fewer long term costs.

According to the study’s lead author, Dr. Cheryl Barnabe, patients who achieved anti-tnf-drugsremission on biologic therapy had fewer hospitalizations, lower monthly cost for over-the-counter medication, needed less help from others for activities of daily living, and fewer lost hours from work compared with patients with moderate to high levels of disease.

For more information on rheumatoid arthritis treatments and other arthritis problems go to:

Arthritis Treatment

And don’t forget to sign up for  free weekly arthritis tips and a free copy of our special report “The Consumer’s Guide to Arthritis”

Just go here Contact